JP6273214B2 - がんを処置するためのインテグリンαｖβ６に対する抗体およびその使用 - Google Patents
がんを処置するためのインテグリンαｖβ６に対する抗体およびその使用 Download PDFInfo
- Publication number
- JP6273214B2 JP6273214B2 JP2014557760A JP2014557760A JP6273214B2 JP 6273214 B2 JP6273214 B2 JP 6273214B2 JP 2014557760 A JP2014557760 A JP 2014557760A JP 2014557760 A JP2014557760 A JP 2014557760A JP 6273214 B2 JP6273214 B2 JP 6273214B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- chain variable
- variable region
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261600499P | 2012-02-17 | 2012-02-17 | |
| US61/600,499 | 2012-02-17 | ||
| US201261602511P | 2012-02-23 | 2012-02-23 | |
| US61/602,511 | 2012-02-23 | ||
| PCT/US2013/026087 WO2013123152A2 (en) | 2012-02-17 | 2013-02-14 | ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509938A JP2015509938A (ja) | 2015-04-02 |
| JP2015509938A5 JP2015509938A5 (enExample) | 2016-01-28 |
| JP6273214B2 true JP6273214B2 (ja) | 2018-01-31 |
Family
ID=48984888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014557760A Expired - Fee Related JP6273214B2 (ja) | 2012-02-17 | 2013-02-14 | がんを処置するためのインテグリンαｖβ６に対する抗体およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US9493566B2 (enExample) |
| EP (1) | EP2814509B1 (enExample) |
| JP (1) | JP6273214B2 (enExample) |
| KR (1) | KR102084806B1 (enExample) |
| CN (2) | CN105017420B (enExample) |
| AU (1) | AU2013221585B2 (enExample) |
| BR (1) | BR112014019861A2 (enExample) |
| CA (1) | CA2862319C (enExample) |
| EA (1) | EA031069B1 (enExample) |
| IL (1) | IL233742B (enExample) |
| MX (1) | MX360141B (enExample) |
| SG (1) | SG11201404354UA (enExample) |
| WO (1) | WO2013123152A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102037119B (zh) | 2008-05-23 | 2015-06-24 | Siwa有限公司 | 促进再生的方法、组合物及设备 |
| CN106232625B (zh) * | 2013-10-01 | 2020-04-24 | 免疫医疗有限公司 | 治疗和诊断过表达α-V-β-6的癌症的方法 |
| PT3057585T (pt) | 2013-10-15 | 2020-10-21 | Seagen Inc | Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando |
| EP3107557B1 (en) | 2014-02-17 | 2021-06-09 | Seagen Inc. | Hydrophilic antibody-drug conjugates |
| US20170233452A1 (en) * | 2014-04-23 | 2017-08-17 | Immusoft Corporation | Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer |
| AU2015318036B2 (en) | 2014-09-19 | 2021-07-01 | Siwa Corporation | Anti-AGE antibodies for treating inflammation and auto-immune disorders |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| IL283726B2 (en) | 2016-02-19 | 2025-05-01 | Siwa Corp | A preparation containing an antibody to advanced glycation end products (AGE) for use in the treatment of breast cancer |
| EP3433278A4 (en) | 2016-03-25 | 2019-11-06 | Seattle Genetics, Inc. | METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF |
| EP3443007A1 (en) | 2016-04-15 | 2019-02-20 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
| KR20240010534A (ko) | 2016-08-09 | 2024-01-23 | 씨젠 인크. | 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체 |
| EA201990890A1 (ru) | 2016-10-18 | 2019-10-31 | Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида | |
| AU2017354041B2 (en) * | 2016-11-01 | 2024-02-01 | Arrowhead Pharmaceuticals, Inc. | Alpha-V beta-6 integrin ligands and uses thereof |
| WO2018107116A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
| JP7244987B2 (ja) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
| JP7527787B2 (ja) | 2017-03-24 | 2024-08-05 | シージェン インコーポレイテッド | グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体 |
| BR112019021471A2 (pt) * | 2017-04-13 | 2020-05-12 | Siwa Corporation | Anticorpo monoclonal humanizado de produto final da glicação avançada |
| WO2018201087A1 (en) | 2017-04-27 | 2018-11-01 | Seattle Genetics, Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
| SG11202002967SA (en) | 2017-11-01 | 2020-05-28 | Arrowhead Pharmaceuticals Inc | Integrin ligands and uses thereof |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| MX2020008267A (es) | 2018-02-20 | 2020-09-21 | Seattle Genetics Inc | Compuestos de auristatina f hidrofoba y conjugados de los mismos. |
| US20240199735A1 (en) * | 2019-07-22 | 2024-06-20 | The Methodist Hospital | Microfibrillar-Associated Protein 5 (MFAP5)-Targeting Monoclonal Antibodies and Methods for Use in Treating Cancer |
| TWI884192B (zh) * | 2019-12-05 | 2025-05-21 | 美商西健公司 | 抗αＶβ６抗體及抗體-藥物結合物 |
| CN115052663B (zh) | 2020-01-08 | 2026-06-09 | 辛瑟斯治疗股份有限公司 | Alk5抑制剂缀合物及其用途 |
| AU2021251875A1 (en) | 2020-04-10 | 2022-11-03 | Seagen Inc. | Charge variant linkers |
| JP2024510435A (ja) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
| WO2022216920A1 (en) | 2021-04-08 | 2022-10-13 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use |
| CA3212610A1 (en) | 2021-04-20 | 2022-10-27 | Philip MOQUIST | Modulation of antibody-dependent cellular cytotoxicity |
| IL308795A (en) | 2021-05-28 | 2024-01-01 | Seagen Inc | Anthracycline antibody conjugates |
| KR20250004952A (ko) | 2022-03-17 | 2025-01-08 | 씨젠 인크. | 캄프토테신 접합체 |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| WO2024137442A1 (en) | 2022-12-21 | 2024-06-27 | Gilead Sciences, Inc. | Combination therapy for treating cancer |
| WO2024263932A2 (en) | 2023-06-23 | 2024-12-26 | Mythic Therapeutics, Inc. | Itgb6-binding proteins and uses thereof |
| WO2025149947A1 (en) | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
| WO2026112478A1 (en) | 2024-11-24 | 2026-05-28 | Mythic Therapeutics, Inc. | Lrrc15-binding proteins, multispecific anti-lrrc15 x anti-tumor-associated antigen (taa) antibodies, conjugation linkers, and methods of use and production thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962643A (en) | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
| NZ502546A (en) | 1997-08-08 | 2002-02-01 | Univ California | Treatment of acute lung injury and fibrosis with antibodies to alpha-v-beta-6 |
| AU2002258808A1 (en) | 2001-04-30 | 2002-11-11 | Eli Lilly And Company | Humanized antibodies |
| CN100509851C (zh) * | 2002-03-13 | 2009-07-08 | 拜奥根Idec马萨诸塞公司 | 抗αvβ6抗体 |
| MY147019A (en) * | 2002-03-13 | 2012-10-15 | Biogen Idec Inc | Anti-alpha v beta 6 antibodies |
| WO2003087340A2 (en) | 2002-04-12 | 2003-10-23 | Raven Biotechnologies, Inc. | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
| US7241598B2 (en) * | 2004-06-29 | 2007-07-10 | The Chinese University Of Hong Kong | Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering |
| EA200700751A1 (ru) * | 2004-10-05 | 2008-06-30 | Элан Фарма Интернэшнл Лимитед | Способы и композиции для улучшения продуцирования рекомбинантного белка |
| KR101281501B1 (ko) * | 2004-12-09 | 2013-07-15 | 얀센 바이오테크 인코포레이티드 | 항인테그린 면역 컨쥬게이트, 방법 및 용도 |
| EP2322560B1 (en) * | 2005-03-10 | 2013-09-04 | Morphotek, Inc. | Anti-mesothelin antibodies |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| KR20080039969A (ko) | 2005-08-31 | 2008-05-07 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Ｇｌａ 도메인을 결합하는 인간 ｆｖｉｉ 단일클론의 항체및 이것의 사용 |
| WO2008112004A2 (en) | 2006-08-03 | 2008-09-18 | Astrazeneca Ab | ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF |
| CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| JP2010506944A (ja) | 2006-10-19 | 2010-03-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インテグリンαＶβ６のアンタゴニストを用いる慢性喘息の処置および予防 |
| AU2009203464A1 (en) * | 2008-01-11 | 2009-07-16 | Forerunner Pharma Research Co., Ltd. | Anti-CLDN6 antibody |
| US20090226442A1 (en) * | 2008-01-22 | 2009-09-10 | Biogen Idec Ma Inc. | RON antibodies and uses thereof |
| CN101959929B (zh) | 2008-03-27 | 2013-05-01 | 泰尔茂株式会社 | 生物体吸收性材料及使用其的生物体内留置物 |
| AU2009245724A1 (en) | 2008-05-09 | 2009-11-12 | Ablynx N.V. | Amino acid sequences directed against integrins and uses thereof |
| JP2010210772A (ja) | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| KR101138460B1 (ko) | 2009-10-12 | 2012-04-26 | 한국생명공학연구원 | 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물 |
| WO2011046309A2 (en) | 2009-10-12 | 2011-04-21 | Korea Research Institute Of Bioscience And Biotechnology | A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof |
| MX361929B (es) | 2010-11-19 | 2018-12-19 | Eisai R&D Man Co Ltd Star | Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes. |
| US20150086570A1 (en) | 2012-03-29 | 2015-03-26 | Biogen Idec Ma Inc. | Biomarkers for use in integrin therapy applications |
-
2013
- 2013-02-14 CN CN201510418545.9A patent/CN105017420B/zh not_active Expired - Fee Related
- 2013-02-14 BR BR112014019861A patent/BR112014019861A2/pt not_active IP Right Cessation
- 2013-02-14 JP JP2014557760A patent/JP6273214B2/ja not_active Expired - Fee Related
- 2013-02-14 MX MX2014009751A patent/MX360141B/es active IP Right Grant
- 2013-02-14 SG SG11201404354UA patent/SG11201404354UA/en unknown
- 2013-02-14 CN CN201380009160.6A patent/CN104220094A/zh active Pending
- 2013-02-14 EA EA201491541A patent/EA031069B1/ru unknown
- 2013-02-14 AU AU2013221585A patent/AU2013221585B2/en not_active Ceased
- 2013-02-14 CA CA2862319A patent/CA2862319C/en active Active
- 2013-02-14 EP EP13749647.7A patent/EP2814509B1/en active Active
- 2013-02-14 WO PCT/US2013/026087 patent/WO2013123152A2/en not_active Ceased
- 2013-02-14 KR KR1020147025536A patent/KR102084806B1/ko not_active Expired - Fee Related
- 2013-02-14 US US14/378,746 patent/US9493566B2/en not_active Expired - Fee Related
-
2014
- 2014-07-22 IL IL233742A patent/IL233742B/en active IP Right Grant
-
2016
- 2016-09-07 US US15/258,699 patent/US20160376368A1/en not_active Abandoned
-
2019
- 2019-09-30 US US16/588,331 patent/US20200031938A1/en not_active Abandoned
-
2021
- 2021-01-08 US US17/144,869 patent/US20210340260A1/en not_active Abandoned
-
2023
- 2023-02-17 US US18/170,742 patent/US20230242648A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013123152A2 (en) | 2013-08-22 |
| EA201491541A1 (ru) | 2016-05-31 |
| KR102084806B1 (ko) | 2020-03-04 |
| IL233742B (en) | 2019-08-29 |
| CA2862319C (en) | 2021-11-30 |
| SG11201404354UA (en) | 2014-10-30 |
| MX2014009751A (es) | 2015-02-24 |
| US20200031938A1 (en) | 2020-01-30 |
| CN105017420B (zh) | 2019-05-28 |
| US20160376368A1 (en) | 2016-12-29 |
| AU2013221585B2 (en) | 2017-03-30 |
| EP2814509A4 (en) | 2015-12-09 |
| MX360141B (es) | 2018-10-24 |
| EA031069B1 (ru) | 2018-11-30 |
| CN105017420A (zh) | 2015-11-04 |
| US9493566B2 (en) | 2016-11-15 |
| CA2862319A1 (en) | 2013-08-22 |
| IL233742A0 (en) | 2014-09-30 |
| JP2015509938A (ja) | 2015-04-02 |
| US20160009806A1 (en) | 2016-01-14 |
| EP2814509A2 (en) | 2014-12-24 |
| US20210340260A1 (en) | 2021-11-04 |
| US20230242648A1 (en) | 2023-08-03 |
| WO2013123152A3 (en) | 2014-11-13 |
| AU2013221585A1 (en) | 2014-08-14 |
| CN104220094A (zh) | 2014-12-17 |
| KR20140127875A (ko) | 2014-11-04 |
| EP2814509B1 (en) | 2018-05-16 |
| BR112014019861A2 (pt) | 2017-07-04 |
| HK1211035A1 (en) | 2016-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230242648A1 (en) | Antibodies to integrin avb6 and use of same to treat cancer | |
| US20230105802A1 (en) | Anti-ntb-a antibodies and related compositions and methods | |
| AU2016276751B2 (en) | CD123 antibodies and conjugates thereof | |
| TWI872044B (zh) | 抗ｃｄ２２８抗體及抗體－藥物共軛體 | |
| KR20220110231A (ko) | 항-αvβ6 항체 및 항체-약물 접합체 | |
| US20210009694A1 (en) | Anti c-met antibodies | |
| TWI591176B (zh) | 抗ｌｉｖ－１之人化抗體類及彼等於治療癌症上之用途 | |
| HK1211035B (en) | ANTIBODIES TO INTEGRIN αvβ6 AND USE OF SAME TO TREAT CANCER | |
| EA046934B1 (ru) | АНТИТЕЛА ПРОТИВ αvβ6 И КОНЪЮГАТЫ АНТИТЕЛО-ЛЕКАРСТВЕННОЕ СРЕДСТВО |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151204 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151204 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161027 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161128 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20161222 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170112 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20161222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170214 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170606 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170818 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171219 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180105 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6273214 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |